title: Organizational issues in conducting tuberculosis screening at a syringe exchange program.
abstract: There has been a rise in tuberculosis (TB) cases in the United States and there is a potent link between human immunodeficiency virus (HIV) and tuberculosis. In New City it is estimated that 40% of the 200,000 injecting drug users are infected with HIV. In addition, the tuberculosis case rate is approximately four times the national average, and one third of these cases occurred in those persons infected with HIV. Drug users have a high prevalence of latent tuberculous infection and are at high risk for progression to active tuberculosis. Drug users are at high risk for both HIV and TB. Although studies have shown the value of incorporating TB services into drug treatment programs, the majority of drug users in the United States are not in drug treatment. We have been evaluating the feasibility of conducting TB screening and directly observed TB preventive therapy for active injecting drug users at a syringe exchange program in New York City. This paper describes issues relating to the implementation of the TB screening program and discusses general and operational issues relevant to integrating medical and public health programs into existing programs serving drug using individuals.
authors.affiliation: Beth Israel Medical Center, Chemical Dependency Institute, New York, NY 10003, USA. dpaone@ix.netcom.com
authors.forename: D
authors.initials: D
authors.lastname: Paone
authors.forename: D C
authors.initials: DC
authors.lastname: Perlman
authors.forename: M P
authors.initials: MP
authors.lastname: Perkins
authors.forename: L M
authors.initials: LM
authors.lastname: Kochems
authors.forename: N
authors.initials: N
authors.lastname: Salomon
authors.forename: D C
authors.initials: DC
authors.lastname: Des Jarlais
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000517:prevention & control; D003219:Confidentiality; D015658:HIV Infections / Q000517:prevention & control / Q000635:transmission; D006679:HIV Seropositivity; D006801:Humans; D008403:Mass Screening / Q000458:organization & administration*; D018671:Needle-Exchange Programs / Q000458:organization & administration*; D009519:New York City; D013594:Syringes; D014376:Tuberculosis / Q000517:prevention & control*